# US 2015/0105293 A1 · Clinical diagnosis of hepatic fibrosis using a novel panel of low abundant human plasma protein biomarkers

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0105293 A1
- Document ID: US20150105293A1
- Status: Published application
- Kind: A1
- Application number: 14/521,813
- Filed: 2014-10-23
- Published: 2015-04-16
- Earliest claimed: 2009-05-14
- Assignees: The Chancellor, Masters and Scholars of the University of Oxford
- Applicants: The Chancellor, Masters and Scholars of The University of Oxford
- Inventors: Bevin Gangadharan; Nicole Titzmann; Raymond A. Dwek
- Web page: https://patentgrep.com/patent/US20150105293A1

## CPC

- G01N 33/5767: {non-A, non-B hepatitis}
- G01N 33/57525: of the liver or pancreas
- G01N 33/6893: {related to diseases not provided for elsewhere}
- G01N 2333/47: Assays involving proteins of known structure or function as defined in the subgroups
- G01N 2333/4728: alpha-Glycoproteins
- G01N 2333/775: Apolipopeptides
- G01N 2333/924: acting on glycosyl compounds (3.2)
- G01N 2500/00: Screening for compounds of potential therapeutic value
- G01N 2800/085: Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- G01N 2800/54: Determining the risk of relapse
- G01N 2800/56: Staging of a disease; Further complications associated with the disease
- G01N 2800/7057: (Intracellular) signaling and trafficking pathways
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The inventors have proposed a novel panel of human plasma protein biomarkers for diagnosing hepatic fibrosis and cirrhosis. Presently there is no reliable non-invasive way of assessing liver fibrosis. A 2D-PAGE based proteomics study was used to identify potential fibrosis biomarkers. Plasma from patients with hepatic cirrhosis induced by infection with the hepatitis C virus (HCV) were analysed. Several proteins associated with liver scarring and potentially also related to viral infection were identified. These proteins include 14-3-3 protein zeta/delta, adiponectin, afamin, alpha-1-antitrypsin, alpha-2-HS-glycoprotein, apolipoprotein C-M, apolipoprotein E, C4b-binding protein beta chain, intact/cleaved complement C3dg, corticosteroid-binding globulin, fibrinogen gamma chain, beta haptoglobin at pH 5.46-5.49, haptoglobin-related protein, hemopexin, immunoglobulin J chain, leucine-rich alpha-2-glycoprotein, lipid transfer inhibitor protein, retinol-binding protein 4, serum paraoxonase/arylesterase 1, sex hormone-binding globulin and zinc-alpha-2-glycoprotein.

## Claims

### Claim at position 1

1-19. (canceled)

### Claim 20

A method of diagnosing hepatic fibrosis, comprising:
a) obtaining a biological sample from a patient in need thereof;
b) determining in the biological sample a level of at least two HF-associated polypeptides, wherein said at least HF-associated polypeptides comprise hemopexin and alpha-2-HS-glycoprotein; and
c) comparing said determined level to a respective control level to determine a positive or a negative diagnosis of said hepatic fibrosis.

### Claim 21 (depends on 20)

The method of claim 20, wherein the biological sample is a sample of serum or plasma of the patient.

### Claim 22 (depends on 20)

The method of claim 20, wherein the at least two HF-associated polypeptides further comprise at least one of 14-3-3 protein zeta/delta, adiponectin, afamin, alpha-1-antitrypsin, apolipoprotein apolipoprotein E, C4b-binding protein beta chain, intact/cleaved complement C3dg, corticosteroid-binding globulin, fibrinogen gamma chain, beta haptoglobin at pH 5.46-5.49, haptoglobin-related protein, immunoglobulin J chain, leucine-rich alpha-2-glycoprotein, lipid transfer inhibitor protein, retinol-binding protein 4, serum paraoxonase/arylesterase 1, sex hormone-binding globulin, zinc-alpha-2-glycoprotein, inter-α-trypsin inhibitor heavy chain H4 fragments, al antichymotrypsin, apolipoprotein L1, prealbumin, albumin, isoforms of CD5 antigen like protein, beta 2 glycoprotein I, α2 macroglobulin and immunoglobulin components, α1, α2 and α chains of haptoglobin, C3, C4 and factor H-related protein 1, prothrombin, clusterin, and angiotensinogen.

### Claim 23 (depends on 20)

The method of claim 20, wherein the at least two HF-associated polypeptides further comprise at least one of zinc-alpha-2-glycoprotein, apolipoprotein E, apolipoprotein L1, clusterin, lipid transfer inhibitor protein, intact/cleaved complement C3dg, and corticosteroid-binding globulin.

### Claim 24 (depends on 20)

The method of claim 20, wherein said determining comprises using an agent that is specific to the HF-associated polypeptide.

### Claim 25 (depends on 24)

The method of claim 24, wherein the agent is an antibody or a functional equivalent thereof that binds the HF associated peptide.

### Claim 26 (depends on 24)

The method of claim 24, wherein said determining is performed using an assay technique.

### Claim 27 (depends on 26)

The method of claim 26, wherein said determining is performed using enzyme linked immunosorbent assay, radio-immunoassay, protein dot blot, Western blot, turbidimetry or nephelometry.

### Claim 28 (depends on 20)

The method of claim 20, wherein said determining is performed by Multiple Reaction Monitoring using mass spectroscopy.

### Claim 29

A method of determining prognosis of hepatic fibrosis, comprising:
a) obtaining a biological sample from a patient in need thereof;
b) determining in the biological sample a level of at least two HF-associated polypeptides, wherein said at least HF-associated polypeptides comprise hemopexin and alpha-2-HS-glycoprotein; and
c) comparing said determined level to a respective control level to determine a positive or a negative prognosis of said hepatic fibrosis.

### Claim 30 (depends on 29)

The method of claim 29, wherein the biological sample is a sample of serum or plasma of the patient.

### Claim 31 (depends on 29)

The method of claim 29, wherein the at least two HF-associated polypeptides further comprise at least one of 14-3-3 protein zeta/delta, adiponectin, afamin, alpha-1-antitrypsin, apolipoprotein apolipoprotein E, C4b-binding protein beta chain, intact/cleaved complement C3dg, corticosteroid-binding globulin, fibrinogen gamma chain, beta haptoglobin at pH 5.46-5.49, haptoglobin-related protein, immunoglobulin J chain, leucine-rich alpha-2-glycoprotein, lipid transfer inhibitor protein, retinol-binding protein 4, serum paraoxonase/arylesterase 1, sex hormone-binding globulin, zinc-alpha-2-glycoprotein, inter-α-trypsin inhibitor heavy chain H4 fragments, α1 antichymotrypsin, apolipoprotein L1, prealbumin, albumin, isoforms of CD5 antigen like protein, beta 2 glycoprotein I, α2 macroglobulin and immunoglobulin components, α1, α2 and α chains of haptoglobin, C3, C4 and factor H-related protein 1, prothrombin, clusterin, and angiotensinogen.

### Claim 32 (depends on 29)

The method of claim 29, wherein the at least two HF-associated polypeptides further comprise at least one of zinc-alpha-2-glycoprotein, apolipoprotein E, apolipoprotein L1, clusterin, lipid transfer inhibitor protein, intact/cleaved complement C3dg, and corticosteroid-binding globulin.

### Claim 33 (depends on 29)

The method of claim 29, wherein said determining comprises using an agent that is specific to the HF-associated polypeptide.

### Claim 34 (depends on 33)

The method of claim 33, wherein the agent is an antibody or a functional equivalent thereof that binds the HF associated peptide.

### Claim 35 (depends on 33)

The method of claim 33, wherein said determining is performed using an assay technique.

### Claim 36 (depends on 35)

The method of claim 35, wherein said determining is performed using enzyme linked immunosorbent assay, radio-immunoassay, protein dot blot, Western blot, turbidimetry or nephelometry.

### Claim 37 (depends on 29)

The method of claim 29, wherein said determining is performed by Multiple Reaction Monitoring using mass spectroscopy.

### Claim 38

A method of scaling the severity of hepatic fibrosis comprising:
a) obtaining a biological sample from a patient in need thereof;
b) determining in the biological sample a level of at least two HF-associated polypeptides, wherein said at least HF-associated polypeptides comprise hemopexin and alpha-2-HS-glycoprotein; and
c) comparing said determined level to a respective predetermines level in a population of patients ranging from no fibrosis to cirrhosis.

### Claim 39 (depends on 38)

The method of claim 38, wherein the biological sample is a sample of serum or plasma of the patient.

### Claim 40 (depends on 38)

The method of claim 38, wherein the at least two HF-associated polypeptides further comprise at least one of 14-3-3 protein zeta/delta, adiponectin, afamin, alpha-1-antitrypsin, apolipoprotein apolipoprotein E, C4b-binding protein beta chain, intact/cleaved complement C3dg, corticosteroid-binding globulin, fibrinogen gamma chain, beta haptoglobin at pH 5.46-5.49, haptoglobin-related protein, immunoglobulin J chain, leucine-rich alpha-2-glycoprotein, lipid transfer inhibitor protein, retinol-binding protein 4, serum paraoxonase/arylesterase 1, sex hormone-binding globulin, zinc-alpha-2-glycoprotein, inter-α-trypsin inhibitor heavy chain H4 fragments, al antichymotrypsin, apolipoprotein L1, prealbumin, albumin, isoforms of CD5 antigen like protein, beta 2 glycoprotein I, α2 macroglobulin and immunoglobulin components, α1, α2 and α chains of haptoglobin, C3, C4 and factor H-related protein 1, prothrombin, clusterin, and angiotensinogen.

### Claim 41 (depends on 38)

The method of claim 38, wherein the at least two HF-associated polypeptides further comprise at least one of zinc-alpha-2-glycoprotein, apolipoprotein E, apolipoprotein L1, clusterin, lipid transfer inhibitor protein, intact/cleaved complement C3dg, and corticosteroid-binding globulin.

### Claim 42 (depends on 38)

The method of claim 38, wherein said determining comprises using an agent that is specific to the HF-associated polypeptide.

### Claim 43 (depends on 42)

The method of claim 42, wherein the agent is an antibody or a functional equivalent thereof that binds the HF associated peptide.

### Claim 44 (depends on 42)

The method of claim 42, wherein said determining is performed using an assay technique.

### Claim 45 (depends on 44)

The method of claim 44, wherein said determining is performed using enzyme linked immunosorbent assay, radio-immunoassay, protein dot blot, Western blot, turbidimetry or nephelometry.

### Claim 46 (depends on 38)

The method of claim 38, wherein said determining is performed by Multiple Reaction Monitoring using mass spectroscopy.
